CJC-1295 + Ipamorelin Stack: The Ultimate GH Peptide Protocol

The CJC-1295 + Ipamorelin combination is consistently cited as the gold standard in growth hormone (GH) peptide science. It achieves something that most individual GH peptides cannot: a large-amplitude, physiologically patterned GH pulse without the side effects — elevated cortisol, prolactin, or aldosterone — that compromise the selectivity of earlier secretagogue protocols.

Understanding why this specific combination works requires understanding the two complementary pathways through which the pituitary releases growth hormone.

The Two-Pathway GH Release System

The pituitary gland releases GH in pulses. Two distinct signaling pathways converge on the pituitary somatotroph cells to trigger and amplify these pulses:

Pathway 1 — GHRH Receptor (GHRHR): Growth Hormone-Releasing Hormone (GHRH), produced in the hypothalamus, binds GHRH receptors on pituitary somatotrophs. This activates adenylyl cyclase → increases cAMP → protein kinase A (PKA) activation → GH granule exocytosis. This pathway controls the amplitude of GH pulses.

Pathway 2 — Ghrelin Receptor (GHSR-1a): Ghrelin, produced primarily in the stomach, binds GHSR-1a receptors on pituitary somatotrophs. This activates the Gαq/11-PLC-IP3 pathway → calcium release from the endoplasmic reticulum → calcium-dependent GH exocytosis. This pathway provides an amplification signal that dramatically increases the size of the GH pulse when activated simultaneously with GHRHR.

The synergistic principle: When both pathways are activated simultaneously, the combined GH release is multiplicative, not additive. Studies show co-administration can produce GH pulses 5–10x larger than either compound alone, while the pulse pattern remains pulsatile and physiological.

CJC-1295: The GHRH Analog

CJC-1295 is a 29-amino acid analog of endogenous GHRH, modified at positions 2, 8, 15, and 27 to increase receptor binding affinity, DPP-IV resistance, and overall stability compared to native GHRH.

CJC-1295 Without DAC vs. With DAC

CJC-1295 is available in two forms with dramatically different pharmacokinetics:

| Property | CJC-1295 Without DAC | CJC-1295 With DAC | |----------|---------------------|------------------| | Also called | "Modified GRF 1-29" | "CJC-1295 DAC" | | Half-life | ~30 minutes | ~8 days | | Mechanism of extended half-life | None — unmodified | Drug Affinity Complex binds albumin | | Dosing pattern | Each injection = single GH pulse | Once or twice weekly; sustained GH elevation | | GH pattern produced | Pulsatile (physiological) | Sustained elevation (non-pulsatile) | | Preferred for stacking | Yes — pulse-based protocols | Less common in pulse protocols |

CJC-1295 without DAC is the preferred form for stacking with Ipamorelin because it produces discrete, pulsatile GH release that mimics natural physiology. Each co-injection with Ipamorelin triggers a defined GH pulse. CJC-1295 with DAC produces a more sustained, blunted GH profile — useful for some educational purposes but less aligned with physiological pulsatile release when combined with acute Ipamorelin dosing.

CJC-1295 Mechanism Details

• Binds GHRH receptors in anterior pituitary with higher affinity than native GHRH
• Increases GH pulse amplitude (amount of GH released per pulse)
• Does not significantly change pulse frequency
• Studies models show 3–7x GH peak concentration increase at relevant doses
• Minimal effect on cortisol, prolactin, or other stress hormones

Ipamorelin: The Selective GHRP

Ipamorelin is a cyclic pentapeptide designed to be the most selective GH secretagogue in the GHRP class. Developed by Novo Nordisk in the late 1990s, it solves the selectivity problem that limited earlier GHRPs.

What Makes Ipamorelin Unique

Earlier GHRPs (GHRP-2, GHRP-6) effectively stimulated GH release but also triggered significant cortisol, prolactin, and ACTH elevation — complicating studies and introducing unwanted side effects. Ipamorelin achieves selective GHSR-1a activation that produces GH release without these off-target effects.

| Compound | GH Stimulation | Cortisol Elevation | Prolactin Elevation | Selectivity | |----------|---------------|---------------------|---------------------|-------------| | Ipamorelin | Strong | Minimal | Minimal | Very high | | GHRP-2 | Very strong | Moderate | Significant | Low | | GHRP-6 | Strong | Significant | Significant | Low | | Sermorelin | Moderate | Minimal | Minimal | High | | MK-677 (oral) | Strong | Minimal | Slight | Moderate-high |

Ipamorelin Pharmacokinetics

• Half-life: ~2 hours (SC administration)
• Time to peak GH: 15–30 minutes post-injection
• Duration of GH elevation: 2–3 hours
• Receptor: GHSR-1a (ghrelin receptor)

Why the Stack Works: Synergistic GH Release

The critical study finding underpinning this stack is that GHRHR activation and GHSR-1a activation are synergistic at the intracellular signaling level:

• GHRHR (CJC-1295) → cAMP/PKA pathway → mobilizes GH granules
• GHSR-1a (Ipamorelin) → calcium release → triggers GH granule exocytosis

Both signals converge on the same GH secretory machinery — calcium-dependent exocytosis — but through upstream pathways that amplify each other. When both receptors are activated simultaneously, the GH response exceeds what either pathway alone could produce.

Studies published in the Journal of Clinical Endocrinology & Metabolism and subsequent animal studies documented combined GH release 5–10x greater than either compound alone when GHRH analogs and GHSR agonists are co-administered.

Studies Dosing Protocols

Dosing Table: CJC-1295 Without DAC + Ipamorelin

| Parameter | CJC-1295 (no DAC) | Ipamorelin | |-----------|-------------------|------------| | Dose per injection | 100–200 mcg | 100–300 mcg | | Typical ratio | 1:1 to 1:1.5 (CJC:Ipa) | — | | Frequency | Match Ipamorelin dosing | 1–3x daily | | Administration | SC injection | SC injection | | Timing | Same injection, same time | See timing section |

Dosing Table: CJC-1295 With DAC (Alternative Protocol)

| Parameter | CJC-1295 With DAC | Ipamorelin | |-----------|-------------------|------------| | Dose | 2 mg | 200–300 mcg | | Frequency | Once weekly | 2–3x daily (separate timing) | | Purpose | Sustained IGF-1 elevation | Acute GH pulses | | Note | GH pattern is less pulsatile | Maintains discrete pulses |

Frequency Options

| Protocol Intensity | CJC-1295 (no DAC) | Ipamorelin | Notes | |-------------------|-------------------|------------|-------| | Conservative | 2x/week (with Ipa) | 2x/week | Minimal intervention | | Standard | 3x/week (with Ipa) | 3x/week | Most common protocol | | Intensive | 1–2x/week + nightly | Nightly | Optimized pre-sleep dosing | | Split protocol | 2x/week | 2–3x/daily | Independent frequency for each |

Timing: Fasted State and Pre-Sleep Administration

Why Fasting Matters

Insulin is directly antagonistic to growth hormone signaling. Elevated insulin (from a recent meal) significantly blunts the GH response to both GHRH analogs and GHRPs. Studies consistently shows that GH secretagogue protocols produce the largest GH pulse when administered in a fasted state — typically at least 2–3 hours after the last meal.

Additionally: Avoid consuming carbohydrates or fats for 30–60 minutes post-injection, as rapid insulin secretion from food can curtail the GH pulse before it fully develops.

Pre-Sleep Timing

Natural GH secretion peaks during slow-wave sleep (Stage 3/4), typically 60–90 minutes after sleep onset. Administering CJC-1295 + Ipamorelin immediately before sleep aligns the pharmacologically induced GH pulse with this natural circadian peak — potentially amplifying the combined effect.

Pre-sleep administration is the most commonly described timing in GH peptide protocols for this reason.

Expected Studies Outcomes

Studies models using CJC-1295 + Ipamorelin over 8–24 week periods have documented the following endpoints:

| Outcome | Evidence | Mechanism | |---------|----------|-----------| | IGF-1 elevation | Strong (animal + human) | GH stimulates hepatic IGF-1 production | | Lean mass increase | Moderate (animal) | GH/IGF-1 promotes protein synthesis | | Body fat reduction | Moderate (animal) | GH-mediated lipolysis (fat breakdown) | | Bone mineral density | Moderate (animal) | GH/IGF-1 bone remodeling | | Sleep architecture improvement | Moderate | GH release during slow-wave sleep | | Wound healing improvement | Moderate | GH-mediated tissue repair | | Recovery acceleration | Moderate | Anabolic/anti-catabolic GH effects |

Human data: Teichman et al. (2006) documented dose-dependent GH and IGF-1 increases in human subjects using CJC-1295 with DAC. While data specifically on the no-DAC + Ipamorelin combination in humans is limited, the mechanistic basis is well established.

Comparison with Sermorelin

Sermorelin is the original GHRH analog — FDA-approved in a clinical formulation — that predates CJC-1295 in the historical timeline.

| Property | CJC-1295 (no DAC) | Sermorelin | |----------|-------------------|-----------| | Amino acids | 29 (modified GHRH) | 29 (native GHRH 1-29) | | Receptor | GHRHR | GHRHR | | Half-life | ~30 minutes | 10–20 minutes | | DPP-IV resistance | Yes (modified AA) | Minimal | | GH pulse amplitude | Moderate-high | Moderate | | Combined with Ipamorelin | Yes, standard | Yes, standard | | Clinical approval history | Studies compound | Approved clinical form exists |

Both compounds work via the same receptor and can be combined with Ipamorelin using equivalent stacking logic. CJC-1295 without DAC's extended half-life compared to Sermorelin may provide a more sustained GHRHR activation window per injection.

View CJC-1295 | View Ipamorelin | View Sermorelin

Storage and Reconstitution

Lyophilized (both compounds):

• Refrigerate at 2–8°C; stable 12–24 months
• Long-term: freeze at -20°C

Reconstituted:

• Bacteriostatic water for both compounds
• Standard concentration: 1 mg/mL (1000 mcg/mL)
• Refrigerate after reconstitution
• Use within 28–30 days

Can CJC-1295 and Ipamorelin be mixed in the same syringe? Many protocols draw both peptides into the same syringe for a single combined injection. Both compounds are water-soluble and compatible. Draw Ipamorelin first, then CJC-1295 (or vice versa), and administer immediately after mixing.

Studies Disclaimer

Important: All information in this guide is provided for educational and educational purposes only. CJC-1295 and Ipamorelin are not approved by the FDA for human therapeutic use. They are sold exclusively for laboratory use. This guide does not constitute medical advice. Always consult a licensed healthcare provider before considering any peptide-related protocol.